Nutriband Inc. (NASDAQ:NTRB) Short Interest Up 22.7% in December

Nutriband Inc. (NASDAQ:NTRB) was the recipient of a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 186,149 shares, an increase of 22.7% from the November 30th total of 151,744 shares. Based on an average daily volume of 23,309 shares, the short-interest ratio is presently 8.0 days. Approximately 3.3% of the shares of the stock are short sold. Approximately 3.3% of the shares of the stock are short sold. Based on an average daily volume of 23,309 shares, the short-interest ratio is presently 8.0 days.

Nutriband Stock Down 3.0%

Nutriband stock traded down $0.14 on Wednesday, hitting $4.54. 27,314 shares of the stock traded hands, compared to its average volume of 64,344. Nutriband has a 1 year low of $3.90 and a 1 year high of $11.78. The firm has a market cap of $55.30 million, a P/E ratio of -1.48 and a beta of 1.89. The company has a current ratio of 7.52, a quick ratio of 7.35 and a debt-to-equity ratio of 0.01. The business’s fifty day simple moving average is $5.34 and its 200 day simple moving average is $6.68.

Nutriband (NASDAQ:NTRB) last issued its quarterly earnings results on Wednesday, December 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.13) by $1.81. Nutriband had a negative net margin of 560.89% and a negative return on equity of 133.22%. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.68 million. As a group, sell-side analysts forecast that Nutriband will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on NTRB. Zacks Research raised Nutriband from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Wall Street Zen lowered shares of Nutriband from a “hold” rating to a “sell” rating in a report on Friday, September 26th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nutriband in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Nutriband has a consensus rating of “Hold” and an average target price of $13.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Nutriband stock. Vanguard Group Inc. raised its stake in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,738 shares of the company’s stock after buying an additional 3,111 shares during the quarter. Vanguard Group Inc. owned about 1.68% of Nutriband worth $1,429,000 at the end of the most recent quarter. 19.70% of the stock is owned by hedge funds and other institutional investors.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.